Kinetics and metabolite profile of insulin glargine (Lantus®)

被引：0
|
作者：
Kuerzel, GU [1 ]
Sandow, J [1 ]
Seipke, G [1 ]
Lang, AM [1 ]
Mass, J [1 ]
Skrzipczyk, HJ [1 ]
机构：
[1] Aventis Pharma, Frankfurt, Germany
来源：
DIABETOLOGIA | 2001年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
798
引用
收藏
页码：A208 / A208
页数：1
相关论文
共 50 条
  • [21] Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
    Wang, Weimin
    Song, Xiang
    Lou, Ying
    Du, Liying
    Zhu, Dalong
    Zhou, Zhiguang
    DIABETES OBESITY & METABOLISM, 2022, 24 (06): : 1094 - 1104
  • [22] Assessing differences in utilization and costs between insulin detemir (Levemir®) and insulin glargine (Lantus®) users
    Borah, B.
    Alemayehu, B.
    Henk, H. J.
    Forma, F. M.
    VALUE IN HEALTH, 2008, 11 (03) : A228 - A228
  • [23] Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
    Ilag, L. L.
    Deeg, M. A.
    Costigan, T.
    Hollander, P.
    Blevins, T. C.
    Edelman, S. V.
    Konrad, R. J.
    Ortmann, R. A.
    Pollom, R. K.
    Huster, W. J.
    Zielonka, J. S.
    Prince, M. J.
    DIABETES OBESITY & METABOLISM, 2016, 18 (02): : 159 - 168
  • [24] Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment
    Christofides, Elena A.
    Stankiewicz, Andrzej
    Denham, Douglas
    Bellido, Diego
    Franek, Edward
    Nakhle, Samer
    Lukaszewicz, Monika
    Reed, John
    Cozar-Leon, Victoria
    Kosch, Christine
    Karas, Piotr
    Fitz-Patrick, David
    Handelsman, Yehuda
    Warren, Mark
    Hollander, Priscilla
    Huffman, David
    Raskin, Philip
    Oroszlan, Tamas
    Lillestol, Michael
    Ovalle, Fernando
    ENDOCRINE PRACTICE, 2024, 30 (09) : 810 - 816
  • [25] Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D)
    Hollander, Priscilla
    Golm, Gregory
    Carofano, Wendy
    Eldor, Roy
    Crutchlow, Michael
    Marcos, Michael
    Rendell, Marc
    Home, Philip
    Gallwitz, Baptist
    Rosenstock, Julio
    DIABETES, 2016, 65 : A238 - A238
  • [26] Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 1 Diabetes (T1D)
    Home, Philip
    Golm, Gregory
    Carofano, Wendy
    Eldor, Roy
    Crutchlow, Michael
    Marcos, Michael
    Rosenstock, Julio
    Hollander, Priscilla
    Gallwitz, Baptist
    DIABETES, 2016, 65 : A78 - A78
  • [27] A cost-utility analysis of insulin glargine (LANTUS®) in the treatment of patients with type 1 diabetes
    Kristensen, FK
    Sverre, JM
    Bustad, S
    VALUE IN HEALTH, 2003, 6 (06) : 682 - 682
  • [28] Prospective audit of the introduction of insulin glargine (Lantus) into clinical practice in type 1 diabetic patients
    Gallen, IW
    Carter, C
    DIABETES CARE, 2003, 26 (12) : 3352 - 3353
  • [29] Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study
    Blevins, Thomas
    Dahl, Dominik
    Rosenstock, Julio
    Ilag, Liza
    Huster, William J.
    Pollom, Robyn K.
    Prince, Melvin J.
    DIABETES, 2014, 63 : A19 - A19
  • [30] No evidence for accumulation of insulin glargine (LANTUS®):: a multiple injection study in patients with Type 1 diabetes
    Heise, T
    Bott, S
    Rave, K
    Dressler, A
    Rosskamp, R
    Heinemann, L
    DIABETIC MEDICINE, 2002, 19 (06) : 490 - 495
12345